1832 Asset Management’s VanEck Biotech ETF BBH Stock Holding History

1832 Asset Management’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,300	Closed	-$264K	–	727
2021 Q3	$264K	Buy	+1,300	New	+$273K	﹤0.01%	640

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

1832 Asset Management's BBH Position: Q4 2021 in Review

1832 Asset Management sold out of VanEck Biotech ETF (BBH) in Q4 2021, closing a stake of 1,300 shares — an estimated $264K sold.

1832 Asset Management first reported a position in BBH in Q3 2021 and held it in 1 quarter. The position peaked at $264K in Q3 2021. 126 funds tracked by Wall St. Rank hold BBH as of Q4 2021.

1832 Asset Management reported no remaining VanEck Biotech ETF position as of Q4 2021 after selling out during the quarter.
1832 Asset Management sold 1,300 VanEck Biotech ETF shares in Q4 2021, an estimated $264K.
1832 Asset Management first reported a position in VanEck Biotech ETF in Q3 2021 and held it in 1 quarter.
1832 Asset Management's VanEck Biotech ETF position peaked at $264K in Q3 2021.
126 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q4 2021.

Based on 1832 Asset Management's 13F filing for Q4 2021, filed 15 Feb 2022.